MedTrace Logo

A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.

NCT02920385 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2017-12-14

No results posted yet for this study

Summary

This trial is conducted in Europe. The aim of this trial is to investigate the influence of oral semaglutide on the pharmacokinetics (the exposure of the trial drug in the body) of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of semaglutide administered orally in healthy subjects.

Conditions

Interventions

DRUG

Semaglutide

Oral administration once daily alone or together with levothyroxine or Placebo

DRUG

SNAC

Oral administration once daily alone or together with levothyroxine or semaglutide

DRUG

Levothyroxine

Oral administration alone or together with SNAC or oral semaglutide

DRUG

Placebo

Oral administration once daily together with semaglutide

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-10
Primary Completion
2017-04-26
Completion
2017-06-16

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02920385 on ClinicalTrials.gov